Global Kidney Cancer Therapeutics and Diagnostics Market to Reach US$ 8.8 Billion by 2032, Stimulated by Rising Prevalence of Kidney Cancer

July 12, 2023 | Healthcare

According to the latest report by IMARC Group, titled “Kidney Cancer Therapeutics and Diagnostics Market Report by Component (Drugs, Diagnostics), Cancer Types (Clear Cell RCC, Papillary RCC, Chromophobe RCC, Transitional Cell Carcinoma, and Others), Application (Hospitals, Pharmaceutical Labs, Genomic Laboratories, and Others), and Region 2024-2032,” the global kidney cancer therapeutics and diagnostics market size reached US$ 5.1 Billion in 2023. Kidney cancer, also known as renal cancer, is diagnosed through a combination of medical history assessment, physical examination, and tests like computed tomography (CT) scan, ultrasound, magnetic resonance imaging (MRI), and positron emission tomography (PET). It can also be diagnosed through biopsy and blood and urine tests. Besides this, its therapeutics encompass a range of treatment options aimed at managing and combating the growth of cancerous cells. It includes various therapies and surgeries, such as radical or partial nephrectomy, which help remove the tumor and affected kidney tissue. Additionally, kidney cancer therapeutics and diagnostics are used for removing cancer cells, controlling the spread, destroying tumors, and assisting physicians in planning treatments.

Global Kidney Cancer Therapeutics and Diagnostics Market Trends:

The increasing prevalence of kidney cancer worldwide due to the aging population, lifestyle factors like smoking and obesity, and genetic predisposition represent one of the key factors driving the market. Additionally, the rising awareness among individuals about kidney cancer symptoms and the importance of early detection and treatment are catalyzing the demand for kidney cancer therapeutics and diagnostics. Apart from this, the increasing use of genomic and personalized medicine for effective treatment approaches is contributing to the market growth. Furthermore, governing agencies of several countries are introducing awareness campaigns and healthcare programs, which is offering a favorable market outlook. Moreover, advancements in targeted therapies, immunotherapies, and personalized medicine and the development of more advanced diagnostic technologies, like novel imaging methods, liquid biopsies, genomic testing, and artificial intelligence (AI)-driven diagnostic tools, are propelling the market growth. Besides this, a rise in the improvement of healthcare infrastructure and facilities are positively influencing the market. Looking forward, the market value is projected to reach US$ 8.8 Billion by 2032, expanding at a CAGR of 6.22% during 2024-2032.

Market Summary:

Based on the component, the market has been bifurcated into drugs [drugs by therapeutic class {targeted therapy, immunotherapy, and others} and drugs by pharmacological class {angiogenesis inhibitors, mTOR inhibitors, monoclonal antibodies, and cytokine immunotherapy (II-2)}] and diagnostics [imaging test, biopsy, blood test, and others]. Drugs currently dominate the market, holding the largest share.
On the basis of the cancer types, the market has been divided into clear cell RCC, papillary RCC, chromophobe RCC, transitional cell carcinoma, and others. Clear cell RCC represents the largest market segment.
Based on the application, the market has been divided into hospitals, pharmaceutical labs, genomic laboratories, and others. At present, hospitals exhibit a clear dominance in the market.
Region-wise, the market has been categorized into North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. Amongst these, North America enjoys the leading position in the market.
The competitive landscape of the market has also been examined, with some of the key players being Bristol-Myers Squibb Company, Exelixis Inc., Genentech Inc. (Roche Holding AG), Novartis AG, and Pfizer Inc.

Report Scope:

Report Features	Details
Base Year of the Analysis	2023
Historical Period	2018-2023
Forecast Period	2024-2032
Units	US$ Billion
Components Covered	Drugs: Drugs by Therapeutic Class, Drugs by Pharmacologic Class Diagnostics: Imaging Test, Biopsy, Blood Test, Others
Cancer Types Covered	Clear Cell RCC, Papillary RCC, Chromophobe RCC, Transitional Cell Carcinoma, Others
Applications Covered	Hospitals, Pharmaceutical Labs, Genomic Laboratories, and Others
Regions Covered	Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered	United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered	Bristol-Myers Squibb Company, Exelixis Inc., Genentech Inc. (Roche Holding AG), Novartis AG, Pfizer Inc., etc.
Customization Scope	10% Free Customization
Report Price and Purchase Option	Single User License: US$ 3899 Five User License: US$ 4899 Corporate License: US$ 5899
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Global Kidney Cancer Therapeutics and Diagnostics Market to Reach US$ 8.8 Billion by 2032, Stimulated by Rising Prevalence of Kidney Cancer

Purchase options

Single User License ~~$3899~~ $2999
Five User License ~~$4899~~ $3999
Corporate User License ~~$5899~~ $4999

Inquire Before Buying

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.